Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 Registration Phase 3 ...

In one study, ChatGPT information on atopic dermatitis received a score of 3.46/5 from physicians assessing its concordance with clinical guidelines. ChatGPT treatment recommendations for atopic ...

SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, announced ...

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.

The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.

Parents of children with atopic dermatitis (AD, also called eczema) know that the allergic condition can mean a heightened risk of developing food allergies. The desire to prevent food allergies ...

One critical focus for Roivant Sciences is its pipeline. Its success is heavily reliant on products like VTAMA, currently ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The study compared the risk and cumulative incidence of requiring glaucoma surgery—such as minimally invasive surgery, ...

The company's FDA-approved drug Sofdra is the first for the common and embarrassing condition of excessive sweating.

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.